Geneva-based femtech start-up TrialHer has converted early demand into paid pilots with two companies in the UK and Europe, and was selected to join the WHO/Europe Public Health Innovation Platform.
TrialHer, a Geneva-based femtech start-up, has secured its first paid pilots and a series of international validations since launching its Innovation Sandbox in February 2026. Founded in 2025 by Hyatt Antognini-Amin, the company operates a women’s health research platform that helps health companies and research institutions co-design and validate solutions with women.
The start-up has converted early demand into paid pilot work with two femtech companies in the United Kingdom and Europe, supporting research validation and participant insight generation. One pilot is underway, with a second scheduled for July, and both form part of a growing pipeline of opportunities with health companies, researchers and institutions seeking better ways to design and validate women’s health products with women from the start.
TrialHer was also selected to join the WHO/Europe Public Health Innovation Platform, where it will contribute to the Equity and Access working group, one of nine priority areas identified by WHO/Europe. The company was further accepted into the QSTP x Merck FemTech Accelerator in Qatar and is building partnerships across Europe, the United States and the MENA region.
Supported by Microsoft for Start-ups, FONGIT and Venture Kick, TrialHer operates with a lean founding team and plans to execute its first pilots, develop its platform and prepare its next fundraising round.
